If you are interested in participating in any of the following studies please take a look at our General Research Brochure and our Contact page. They contain useful information that will help you to make an informed decision regarding research participation and also includes a glossary of terms often used to describe our studies. If you are interested in taking part in one of the following trials, please call or e-mail us for more information.

Drug and Alcohol Dependence:

• Prescription Opiate Addiction Treatment Study (POATS)

A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Individual Drug Counseling for Opioid Analgesic (pain killers) Dependence. Currently recruiting.

Please call (917) 576-9470 or view our Research Brochure and Recruitment Flyer for more information.

• Opiate Dependence Probuphine Implant Treatment Study (Open Label)

An Open Label, Multi-Center Study of Probuphine in Patients with Opioid Dependence. Plan to begin recruitment May 2008.

• Methamphetamine Abusers Medication Treatment Study

• Methamphetamine Brain Imaging Study

White Matter Changes in Methamphetamine Abuse. Currently recruiting.

• Medication Study for Cigarette Smokers

Placebo-Controlled Study of Varenicline Effects on Nicotine Withdrawal Followed by a Test of Smoking Topography, Reward, and Reinforcement. No longer recruiting.

• Cue-Induced Cocaine Craving Study

A Placebo-Controlled Study of Valproate Effects on Cue-Induced Cocaine Craving. No longer recruiting.

• Cocaine Dependence Medication Treatment Study

Vigabatrin (CP-109) for Treatment of Cocaine Dependence: A Phase II Study. Plan to begin recruitment March 2008.

• Crystal Methamphetamine Addiction Treatment Study

NIDA-MDS-BupropionMeth-0001. Plan to begin recruitment Summer 2008.

• Cocaine Vaccine Study

Multisite Controlled Trial of Cocaine Vaccine (5 of 6) New York University Treatment Site. Plan to begin recruitment Summer 2008.

• Brain Imaging Study of Cocaine Addiction

Functional and Structural Connectivity in Cocaine Addiction. Plan to begin recruitment Summer 2008.

• Patient Feedback Study

A Randomized, Controlled, Multi-Site Study of the Effect of Patient Feedback on Rates of Attendance and Abstinence in Outpatient Substance Treatment Programs. In progress.

For more information, please visit www.patient-feedback.org/

• Mentorship for Alcohol Problems (MAP-Alcohol). Currently recruiting.

• Mentorship for Addiction Problems to Aid in Engagement to Treatment (MAP-Engage). Currently recruiting.

• Opiate Dependence Probuphine Implant Treatment Study

A Randomized, Double Blind, Placebo Controlled, Multi-Center Study of Probuphine in Patients with Opioid Dependence. No longer recruiting.

• Opiate Dependence Probuphine Implant Treatment Extension Study

An Open-Label, Multi-Center Extension Study of Probuphine in Patients with Opioid Dependence. No longer recruiting.

Attention Deficit Hyperactivity Disorder (ADHD):

Please view our ADHD Brochure for more information.

• ADHD Symptom Rating Scale Study

Comparison of Self and Clinician Administered Ratings of Symptoms in Patients with Attention Deficit Hyperactivity Disorder (ADHD). Currently recruiting.

• Treatment Outcome Study for Young Adults with ADHD

A Double-Blind Study of Atomoxetine Hydrochloride versus Placebo for the Treatment of ADHD in Young Adults with an Assessment of Associated Functional Outcomes. Currently recruiting.

• Comparison Study of Immediate Release and Extended Release Adderall

A Within-Subject Cross-over Comparison between Immediate Release and Extended Adderall. Currently recruiting.

• fMRI Study of ADHD and Executive Function

A Functional Magnetic Resonance Imaging (fMRI) Study of the Impact of Reward Anticipation on Executive Function in Adolescents and Adults with ADHD and Normal Controls. Currently recruiting.

• Adult ADHD Treatment With Vyvanse

Effectiveness and Duration of Effect of Open Treatment in Adult ADHD Patients Treated with Lisdexamfetamine Dimesylate –LDX (Vyvanse).

• Adult ADHD Investigational Medication Treatment Study

A Phase IIA, Randomized, Double-Blind, Placebo Controlled, Three-Treatment, Two-Period Crossover Study of the Efficacy and Safety of Two Doses of PF-03654746 in Adults with Attention Deficit Hyperactivity Disorder (ADHD). Currently recruiting.

• Efficacy and Safety study of Org 26576 for Adult ADHD

A Double Blind, Placebo Controlled, Randomized, Two Period 4-arm Trial to Investigate the Dose-Related Efficacy and Safety of Org 26576 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Plan to begin recruitment June 2008.

• Cardiovascular study of Concerta for Adult ADHD

Cardiovascular Tolerability of OROS-Methylphenidate (Concerta®) in Normotensive Adults with Attention Deficit Hyperactivity Disorder (ADHD) and Treated Primary Essential Hypertension. In planning.

• Open-label Extension Study of ABT-089 for Adult ADHD

M06-889: Phase II: The Long-Term Safety and Tolerability of ABT-089 in Adults with Attention-Deficit Hyperactivity Disorder (ADHD): An Open-Label Extension Study. No longer recruiting.

• ADHD Treatment with Atomoxetine in a Residential Substance Abuse Treatment Facility

A 10-Week Open Label Trial of Atomoxetine for ADHD was given to Patients with Substance Abuse Disorder and ADHD at Odyssey House. No longer recruiting.

Neuroimaging:

• fMRI Study of ADHD and Executive Function

A Functional Magnetic Resonance Imaging (fMRI) Study of the Impact of Reward Anticipation on Executive Function in Adolescents and Adults with ADHD and Normal Controls. Currently recruiting.

• Methamphetamine Brain Imaging Study

White Matter Changes in Methamphetamine Abuse. Currently recruiting.

Other States of Pathological Restlessness:

• Incidence of Akathisia in Patients Treated with Aripiprazole. Currently recruiting.

Other Ongoing Studies:

• Risperidone Treatment for Veterans with PTSD

VA Cooperative Study #504: Risperidone Treatment for Military Service Related Chronic PTSD. Currently recruiting.

• Risperidone Consta Treatment for Veterans with Schizophrenia

VA Cooperative Study #555: Long-Acting Injectable Risperidone in the Treatment of Schizophrenia. Currently recruiting.

Healthy Controls:

• We are not currently recruiting healthy controls.